Annual report pursuant to Section 13 and 15(d)

RELATED PARTIES BALANCES AND TRANSACTIONS (Details Narrative)

v3.19.1
RELATED PARTIES BALANCES AND TRANSACTIONS (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Jul. 04, 2018
Dec. 31, 2018
Dec. 31, 2017
Related Party Transaction [Line Items]      
Value of cash received     $ 1,380
Number of shares outstanding   3,801,522 3,935,865
Financial expenses     $ 549
Description of right to exchange common stock   The significant shareholder has the right to exchange an additional 50,000 common shares at their discretion.  
Series C Preferred Stock [Member]      
Related Party Transaction [Line Items]      
Conversion of common stock into preferred (in shares)   250,000  
Separation and Release Agreement [Member] | Dr. Zumeris and Janina Zumeris [Member]      
Related Party Transaction [Line Items]      
Consulting payments $ 18    
Shares issued price per share (in dollars per share) $ 4.45    
Value of cash received $ 950    
Description of payment term In addition, if the Company (i) grants a license for the skin rejuvenation technology, then the Company will pay Dr. Zumeris 10% from the payments received by the Company until an aggregate amount of $100,000 has been paid to Dr. Zumeris, (ii) sells the skin rejuvenation technology and/or the rights to such as a standalone product, the Company will pay Dr. Zumeris $100,000 from the proceeds of such sale, or (iii) sells the skin rejuvenation devices, the Company will pay Dr. Zumeris $5 per unit an aggregate amount of $100,000 has been paid to Dr. Zumeri.    
Separation and Release Agreement [Member] | Dr. Zumeris and Janina Zumeris [Member]      
Related Party Transaction [Line Items]      
Exercise price (in dollars per share)   $ 4.45  
Costs and expense   $ 108